CPCRA researchers present OI studies at Vancouver.
Bowersox
J
J
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000517:prevention & control*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000517:prevention & control*; D002648:Child; D017291:Clarithromycin / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004279:DNA, Viral; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008976:Molluscum Contagiosum / Q000150:complications / Q000453:epidemiology; D008977:Molluscum contagiosum virus / Q000235:genetics*; D015337:Multicenter Studies as Topic; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D015242:Ofloxacin / Q000627:therapeutic use; D010349:Patient Compliance; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D017422:Sequence Analysis, DNA; D014376:Tuberculosis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D000995:Antitubercular Agents; D004279:DNA, Viral; D011718:Pyrazinamide; D004977:Ethambutol; D015725:Fluconazole; D015242:Ofloxacin; D017291:Clarithromycin; D007538:Isoniazid; D012293:Rifampin